

***Fiscal Year 2021 Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Applied Research Award (ARA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-PRORP-ARA</p>	<p>Independent investigators at all academic levels (or equivalent)</p>	<ul style="list-style-type: none"> • Supports applied research applications focused on advancing optimal treatment and restoration of function for individuals with musculoskeletal injuries sustained during combat, combat-related activities, and non-battle injuries that impact unit readiness and the ability to return to duty/work. • Proposed research should be supported by preliminary and/or published data and have the potential to make significant advancements toward clinical translation. • <i>Clinical research and clinical trials are not allowed under this award mechanism.</i> • Applications must address one of the following FY21 PRORP ARA Focus Areas: <ul style="list-style-type: none"> ○ Limb Stabilization and Protection ○ Retention Strategies <ul style="list-style-type: none"> – Battlefield Care – Return to Duty ○ Osseointegration • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$725,000 for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): May 27, 2021 5:00 p.m. Eastern time</p> <p>Application: September 10, 2021 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award (CTA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-PRORP-CTA</p>	<p>Independent investigators at all academic levels (or equivalent)</p>	<ul style="list-style-type: none"> • Supports rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return to duty/work rates. • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date. • Applications must address one of the following FY21 PRORP CTA Focus Areas: <ul style="list-style-type: none"> ○ Limb Stabilization and Protection ○ Retention Strategies <ul style="list-style-type: none"> – Battlefield Care – Return to Duty ○ Translation of Early Findings <ul style="list-style-type: none"> – Soft Tissue Trauma – Fracture-Related Infection • Applications submitted to address the <i>Translation of Early Findings – Soft Tissue Trauma</i> Focus Area <u>and</u> include the Rehabilitation Option are eligible for Research Level 2. • All applications, regardless of the selected Focus Area, are eligible for Research Level 1. • <i>Funding must support a clinical trial and may not be used for animal or preclinical research studies.</i> • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<p>Research Level 1:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.25 million (M) for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. <p>Research Level 2:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.75M for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): May 27, 2021 5:00 p.m. Eastern time</p> <p>Application: September 10, 2021 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Translational Research Award (CTRA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-PRORP-CTRA</p>	<p>Independent investigators at all academic levels (or equivalent)</p>	<ul style="list-style-type: none"> • Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial. • <i>Funding must support clinical research studies involving humans.</i> • Preliminary data relevant to the proposed research project are required. • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration <i>within 12 months of the award date.</i> • Applications must address one of the following FY21 PRORP CTRA Focus Areas: <ul style="list-style-type: none"> ○ Retention Strategies <ul style="list-style-type: none"> – Battlefield Care – Return to Duty ○ Tissue Regeneration Therapeutics ○ Compartment Syndrome ○ Osseointegration ○ Prosthetic and Orthotic Devices • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.5M for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): May 27, 2021 5:00 p.m. Eastern time</p> <p>Application: September 10, 2021 11:59 p.m. Eastern time</p>